Skip to Main Content
Health Metadata Commons
Feedback
Documentation
Login
Home
Search Metadata Commons
Metadata Submission
Resources
Biodiversity Data Sources
Go Back
Project
Metadata Commons Identifier
HMC000048
Required
Project Title
Better biomarkers for transplantation
Required
Project Description
<p><span style="color: rgb(38, 38, 38); font-family: system-ui, -apple-system, 'system-ui', 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 13px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Transplantation is the best treatment for many patients with heart, kidney, and liver failure. However, transplant rejection is a serious complication that reduces graft and patient survival, and decreases the health and other benefits of this treatment. The lack of simple tests to predict or diagnose rejection remains a major problem in the management of transplant recipients. Tissue biopsies remain the best test currently available, but are invasive, expensive, and have some risk to the patient.</span><br style="box-sizing: border-box; outline-color: var(--ut-focus-outline-color,-webkit-focus-ring-color); clear: both; color: rgb(38, 38, 38); font-family: system-ui, -apple-system, 'system-ui', 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 13px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(38, 38, 38); font-family: system-ui, -apple-system, 'system-ui', 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 13px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">The objectives of this study are to identify diagnostic and prognostic biomarkers of acute and chronic rejection for heart, kidney and liver transplant patients.</span></p>
Project Funder(s)
Genome British Columbia, Genome Canada, Novartis Pharma, IBM, Astellas, St. Paul's Hospital Foundation
Project Institution(s)
University of British Columbia
Project Investigator(s)
Bruce McManus
,
Paul Keown
,
W Robert McMaster
Contact Investigator...
Data Access Request URL*
Keywords
cardiac transplant, renal transplant, liver transplant, acute rejection, chronic rejection, diagnostic, prognostic, biomarkers
Publication Link
https://pubmed.ncbi.nlm.nih.gov/21076371/
Study Completed
Cohort
Cohort Name
Biomarkers in Transplantation 1 (BiT1)
Required
Study Design
Observational
Cohort Size
767
Disease/Condition Studied
liver transplant, kidney transplant, heart transplant, end-stage organ failure
Enrollment Time Window
2004-2008
Enrollment City
Biobanking Consent Available
Medical History Available
Ethnicity Availability
Time Course
Patient Phenotypes
no acute rejection, mild acute rejection, severe acute rejection, no chronic rejection, chronic rejection
Patient Outcomes
mortality, viral infections
Clinical Data Types Available
biopsy results, demographics, lab results, medication, viral infections, vital signs
Time Course Data Points
pre-transplant, at transplant, 0.5, 1, 2, 3, 4, 8, 12, and 26 weeks; then every 6 months through year 3 post transplant
Groups
Samples and Omics